MapMyGenome launches pharmacogenomics solution covering more than 165 drugs

MapMyGenome has launched MedicaMap, a comprehensive pharmacogenomics solution that covers more than 165 drugs across multiple therapeutic areas. The launch marks a significant milestone in making precision medicine accessible to Indian patients and healthcare providers.

Covering 165+ Drugs Across Therapeutic Areas

MedicaMap's coverage spans cardiology (including clopidogrel, warfarin, statins), psychiatry (antidepressants, antipsychotics, mood stabilizers), neurology (antiepileptics, pain medications), oncology (chemotherapy agents), gastroenterology, and more. The breadth of coverage makes MedicaMap one of the most comprehensive pharmacogenomic tests available in India.

Key Genes Analyzed

MedicaMap analyzes variants in the most clinically important pharmacogenomic genes, including CYP2D6, CYP2C19, CYP2C9, CYP3A4/5, SLCO1B1, DPYD, TPMT, UGT1A1, and HLA variants (HLA-B*5701, HLA-B*1502, HLA-A*3101). These genes collectively influence the metabolism, efficacy, and safety of the majority of commonly prescribed medications.

Clinical Impact

Pharmacogenomic variants can cause dramatic differences in drug response between individuals. CYP2D6 poor metabolizers may accumulate standard doses of many antidepressants and antipsychotics to toxic levels. CYP2C19 poor metabolizers cannot activate clopidogrel, leaving them at elevated cardiovascular risk despite treatment. HLA-B*1502 carriers face life-threatening skin reactions to carbamazepine. MedicaMap identifies these variants before treatment begins, enabling safer and more effective prescribing.

Simple, Accessible Testing

MedicaMap uses a simple saliva sample collected at home, with results delivered digitally. The test is processed in MapMyGenome's NABL-certified laboratory, ensuring the highest standards of analytical accuracy.